Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ANAPTYSBIO, INC Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.	United States of America	ANAB
ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.	Türkiye	ANGEN
ANAVEX LIFE SCIENCES CORP. Developing precision therapeutics for neurodegenerative and CNS disorders.	United States of America	AVXL
Anbio Biotechnology Develops and supplies in vitro diagnostic solutions for human and veterinary markets.	United States of America	NNNN
Anebulo Pharmaceuticals, Inc. Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.	United States of America	ANEB
AnGes, Inc. Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.	Japan	4563
ANIMALCARE GROUP PLC Develops & sells veterinary prescription & OTC medicines for professionals worldwide.	United Kingdom	ANCR
ANI PHARMACEUTICALS INC Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.	United States of America	ANIP
Annexin Pharmaceuticals AB Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.	Sweden	ANNX
Annexon, Inc. Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.	United States of America	ANNX